Age, Biography and Wiki

Alexander Levitzki was born on 13 August, 1940 in Jerusalem, Mandatory Palestine, is an Israeli biochemist. Discover Alexander Levitzki's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 83 years old?

Popular As N/A
Occupation N/A
Age 83 years old
Zodiac Sign Leo
Born 13 August, 1940
Birthday 13 August
Birthplace Jerusalem, Mandatory Palestine
Nationality Israel

We recommend you to check the complete list of Famous People born on 13 August. He is a member of famous with the age 83 years old group.

Alexander Levitzki Height, Weight & Measurements

At 83 years old, Alexander Levitzki height not available right now. We will update Alexander Levitzki's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Alexander Levitzki Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Alexander Levitzki worth at the age of 83 years old? Alexander Levitzki’s income source is mostly from being a successful . He is from Israel. We have estimated Alexander Levitzki's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Alexander Levitzki Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

1940

Alexander Levitzki (Hebrew: אלכסנדר לויצקי; born 13 August 1940) is an Israeli biochemist who is a professor of biochemistry at the Alexander Silberman Institute of Life Sciences, the Hebrew University of Jerusalem.

Levitzki was born in 1940 in Palestine.

He completed his M.Sc.

in chemistry from the Hebrew University of Jerusalem in Israel.

1968

He received his Ph.D. in biochemistry and biophysics from the Hebrew University of Jerusalem and the Weizmann Institute of Science, in 1968.

From 1968 to 1971, he was a post-doctoral fellow at the Department of Biochemistry, University of California at Berkeley in California, with Professor Daniel E. Koshland, Jr., where he worked in particular on negative cooperativity and half-of-the-sites reactivity.

Contrary to the common misconception, Levitzki is not a descendant of the Hebrew Levite tribe.

1970

In 1970, Levitzki became a senior scientist at the Department of Biophysics, Weizmann Institute of Science.

1974

In 1974, he became an associate professor at the same institute.

In 1974, he became an associate professor at the Hebrew University of Jerusalem.

1976

In 1976, he was promoted to professor of biochemistry at the Hebrew University of Jerusalem.

He has been visiting scientist at the National Cancer Institute, and Fogarty International Scholar, NIH, Bethesda, Maryland, visiting scholar at Stanford University in California, visiting professor at the University of Oregon (Eugene) and visiting professor at the University of California, San Francisco.

He is also a member of the Israel Academy of Sciences and Humanities and was the head of its science section.

Levitzki is known for developing specific chemical inhibitors of cancer-induced protein kinases.

He was the first to develop systematically tyrosine phosphorylation inhibitors (tyrphostins) against a wide spectrum of protein tyrosine kinases.

1990

In 1990, he was awarded the Israel Prize, in life sciences (following in the footsteps of his father, Jacob Levitzki, who had received the prize, for exact sciences, in 1953).

1993

Levitzki demonstrated (1993) that such an inhibitor of Bcr-Abl kinase induces death of chronic myeloid leukemia (CML) cells.

1996

This work led to the development of Gleevec by Novartis (1996), which is currently used, with great success, for therapy of patients afflicted by this disease.

Levitzki also pioneered the inhibitors of EGF receptor, PDGF receptor, Her-2/neu, Jak-2, VEGFR and peptide based cell permeable PKB/Akt inhibitors.

Levitzki also showed that PDGFR kinase inhibitors (PDGFR directed tyrphostins), released from nanoparticles or from a drug eluting stent can be used to inhibit restenosis after balloon angioplasty.

2005

In 2005, he was awarded the Wolf Prize in Medicine for "pioneering signal transduction therapy and for developing tyrosine kinase inhibitors as effective agents against cancer and a range of other diseases".

2006

In 2006 his research team developed a method for inducing brain tumor cells to "commit suicide".